Table 2.

Characteristics of iHCC cases.

Case number	Transplant year	Diagnosis	Number of lesions	Diameter of largest nodule (cm)	TTV	Highest AFP	Method of screening	Screening center
1	1994	AC	1	4.0	35.5	—	US	Tertiary
2	1995	HCV, AC	1	1.5	1.8	—	US	Primary
3	1995	HCV, Hemo.	1	0.8	0.3	—	US	Primary
4	1995	HCV	1	0.8	0.3	10	US	Tertiary
5	1998	HBV, AC	4	3.8	33.4	4	US	Tertiary
6	1998	AC	3	2.0	6.5	1	CT	Primary
7	1999	HCV	1	0.8	0.3	11	CT	Tertiary
8	1999	PSC	2	5.0	66.3	4	CT	Tertiary
9	1999	HCV	1	4.0	33.5	2	CT	Tertiary
10	2000	Crypt.	1	0.8	0.3	3	CT	Tertiary
11	2000	AC	1	1.0	0.5	3	CT	Tertiary
12	2000	A1AD, HCV	4	4.0	38.7	3	CT	Primary
13	2001	AC	5	3.2	27.5	2	CT	Primary
14	2001	HCV	1	1.5	1.8	30	CT	Tertiary
15	2001	HCV, AC	7	1.5	4.3	2	CT	Tertiary
16	2002	Hemo., AC	5	2.0	4.4	17	CT	Tertiary
17	2002	HCV	1	0.9	0.4	21.1	CT	Tertiary
18	2003	HCV	2	1.1	0.9	16	CT	Primary
19	2003	HCV	2	2.0	9.0	10	CT	Primary
20	2003	HCV, AC	1	2.4	7.2	11	CT	Primary
21	2004	Crypt.	1	1.9	3.6	4	CT	Primary
22	2005	HCV, AC	1	0.7	0.1	41	MRI	Primary
23	2005	HCV, AC	1	0.6	0.1	8	MRI	Tertiary
24	2005	HCV	2	1.7	3.0	15	MRI	Tertiary
25	2005	PBC, AC	5	3.2	33.0	16	MRI	Primary
26	2007	HCV	1	2.3	1.0	4	MRI	Tertiary
27	2007	AC	1	1.5	0.3	3	MRI	Primary
28	2007	Hemo.	1	1.5	2.3	3	MRI	Tertiary
29	2009	PSC	1	0.6	0.1	10	MRI	Primary
30	2009	HBV	2	4.5	61.9	10	MRI	Primary
31	2009	Hemo., NAFLD	1	1.2	0.9	23	MRI	Tertiary
32	2009	HCV, AC	1	1.5	1.7	3	MRI	Primary

AC, alcoholic cirrhosis; PSC, primary sclerosing cholangitis; Hemo., hemochromatosis; Crypt., cryptogenic cirrhosis; A1AD, alpha-1 antitrypsin deficiency; PBC, primary biliary cirrhosis; NAFLD, nonalcoholic fatty liver disease; US, abdominal ultrasound; CT, computed tomography; MRI, magnetic resonance imaging.